<DOC>
	<DOC>NCT00882557</DOC>
	<brief_summary>The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.</brief_summary>
	<brief_title>Study to Evaluate Daptomycin Given During Dialysis and After Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Written informed consent prior to any studyrelated procedure not part of normal medical care; Male or female ≥ 18 years of age; If female of childbearing potential; willing to practice reliable birth control measures during study treatment and for at least 28 days after study completion, not lactating or pregnant, and has a documented negative pregnancy test result within 24 hours prior to study medication administration; Endstage renal disease on stable (for at least 2 weeks) hemodialysis regimen, three times weekly using highflux membranes; Functioning hemodialysis access (for example, graft or fistula); Considered to be in appropriate health for study entry by the Investigator (for example, no acute, debilitating medical problems) and appropriate candidate for completing study treatment; If taking concomitant medications, subject must be on a relatively stable dose for at least two weeks prior to study drug administration. Received an investigational drug (including experimental biologic agents) within 30 days of study drug administration; Has received any dose of daptomycin within 7 days prior to study drug administration; Known to be allergic or intolerant to daptomycin; Evidence of active ongoing infection; Known human immunodeficiency virus (HIV) infection with CD4 count ≤ 200 cells/mm3; Active illicit drug use or alcohol abuse; Myocardial infarction within last 6 months; Subject with a history of muscular disease (for example, polymyositis, muscular dystrophy); Subject with a history of neurological disease (for example, Guillain Barré, multiple sclerosis), except stroke &gt; 6 months prior to study entry; Intramuscular injection within 7 days of study drug administration; Body mass index (BMI) ≤ 18.5 or ≥ 40 kg/m2 (BMI = weight [kg]/height [m2]); WBC ≥ 12, 000 cells/mm3 or ≤ 2500 cells/ mm3; Neutropenic subject with absolute neutrophil count ≤ 500 cells/mm3; Baseline CPK values ≥ 3X ULN (upper limit of normal); Alanine aminotransferase (ALT) &gt; 5XULN; Aspartate aminotransferase (AST) &gt; 5XULN; Hemoglobin ≤ 9 gm/dL; Is considered unlikely to comply with study procedures or to return for scheduled posttreatment evaluations; History of rhabdomyolysis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>End-stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>chronic renal failure</keyword>
</DOC>